We have demonstrated here that Shp2 was overexpressed in lung cancer tissue samples from a group of NSCLC patients from Beijing, and that in lung cancer cells, Shp2 promoted proliferation, reduced gefitinib sensitivity, and enhanced migration through activation of the ERK1/2 pathway. The gene discussed is PTPN11; the disease is lung cancer.